TransMedics Group, Inc.

TransMedics Group, Inc.

TMDX·NASDAQ

$69.69

+3.2%
HealthcareMedical - Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

At a Glance

Live Snapshot
Market Cap$2.41B
EPS5.6000
P/E Ratio12.44
Earnings Date07/29/2026

tmdx

Stock Based Compensation

Last Annual Value

36.86M

3-Year CAGR

53%

5-Year CAGR

72%

10-Year CAGR

96%

TransMedics Group, Inc.

TransMedics Group, Inc. Competitors Analysis of Stock Based Compensation

TMDX · NASDAQ
CompanyStock Based Compensation
CAGR 3Y
CAGR 5Y
CAGR 10Y
36.86M
23.0%39.9%95.6% 
29.70M
11.4%24.2%N/A
63.22M
13.2%16.0%21.8%
0.00
N/AN/AN/A
643.01M
631.2%N/AN/A
59.90M
11.6%19.1%N/A
26.00M
7.4%18.8%N/A
59.42M
34.2%116.7%N/A
87.65M
-18.1%0.3%N/A
39.96M
9.4%33.1%35.2%
IMVT logo
Immunovant, Inc.
NASDAQ:IMVT
55.72M
19.9%N/AN/A
TransMedics Group, Inc.

TransMedics Group, Inc. Fair Value Envelope

TMDX · NASDAQ

Our analysis suggests that TMDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $69.69, this represents a potential HIDDEN relative to our calculated worth for TransMedics Group, Inc..

Intrinsic Value
Current Price: $69.69